Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

BACKGROUND: Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Excellence (NICE) preli...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Zhong, Lixian, Pon, Vickie, Srinivas, Sandy, Nguyen, Nicole, Frear, Meghan, Kwon, Sherry, Gong, Cynthia, Malmstrom, Robert, Wilson, Leslie
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Public Library of Science 2013
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661482/
https://ncbi.nlm.nih.gov/pubmed/23717582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0064275
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन